Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFDA Aims To Fully Implement New GSP Standards By 2016

This article was originally published in PharmAsia News

Executive Summary

China FDA recently requested full new good storage practices (GSP) implementation before 2016, while giving companies that handle pharmaceuticals a grace period to the end of June next year to get assessments in order.

You may also be interested in...



NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.

New Zealand Reverse-Switches Codeine Judging Risks Outweigh Benefits

New Zealand is the latest country to reverse-switch all codeine-containing OTC drugs to prescription-only status following a protracted consultation process, during which industry's protestations fell on deaf ears.

Topics

UsernamePublicRestriction

Register

SC084719

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel